PIN Pharma, Inc.

PIPELINE

PIN Pharma is focused on developing its lead compound, PIN-2, for immune modulation in cancer therapies, and completed a first-in-human study in June 2018. This study demonstrated that PIN-2 was safe, had a rapid onset of action, and it could produce marked increases in circulating TNF-alpha. The final report was issued in December 2018, and PIN is currently looking for a partner to carry forward the development of this novel immune modulator.